Alzheimer's disease: More than a 'cholinergic disorder' - Evidence that cholinergic-monoaminergic interactions contribute to EEG slowing and dementia

Behavioural Brain Research

Volumn 115, Issue 2, 2000, Pages 235-249

  Dringenberg, Hans C ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Acetylcholine; Alzheimer's disease; Behavior; EEG; Monoamines; Serotonin

Indexed keywords

ACETYLCHOLINE; MONOAMINE; SEROTONIN;

ALZHEIMER DISEASE; BEHAVIOR; BRAIN ATROPHY; BRAIN CORTEX; CHOLINERGIC SYSTEM; CHOLINERGIC TRANSMISSION; COGNITION; DEMENTIA; ELECTROENCEPHALOGRAPHY; HIPPOCAMPUS; LEARNING; MEMORY; MONOAMINERGIC SYSTEM; NEOCORTEX; NERVE CELL NETWORK; NERVE DEGENERATION; NEUROTRANSMITTER RELEASE; NONHUMAN; NORADRENERGIC SYSTEM; PREDICTION; PRIORITY JOURNAL; REVIEW; SEROTONINERGIC SYSTEM; THEORY;

EID: 0033805791     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-4328(00)00261-8     Document Type: Article

References (112)

1. Allen N.H.P., Burns A. The treatment of Alzheimer's disease. J. Psychopharmacol. 9:1995;43-56.
2. Alzheimer A. Uber eine eigenartige erkrankung der himrinde. Allg. Z. Psychiatr. Psych- Gerichtliche Med. 64:1907;146-148.
3. Ang L.-C., Shul D. Peptidergic neurons of subcortical white matter in aging and Alzheimer's brain. Brain Res. 674:1995;329-335.
4. Baker G.B., Reynolds G.P. Biogenic amines and their metabolites in Alzheimer's disease: noradrenaline, 5-hydroxytryptamine and 5-hydroxyindole-3-acetic acid are depleted in hippocampus but not in substantia innominata. Neurosci. Lett. 100:1989;335-339.
5. Bartus R.T., Dean R.L. III, Beer B., Lippa A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science. 217:1982;408-417.
6. Baxter M.G., Chiba A.A. Cognitive functions of the basal forebrain. Curr. Opin. Neurobiol. 9:1999;178-183.
7. Beiko J., Candusso L., Cain D.P. The effect of nonspatial water maze pretraining in rats subjected to serotonin depletion and muscarinic receptor antagonism: a detailed behavioural assessment of spatial performance. Behav. Brain Res. 88:1997;201-211.
8. Belardetti F., Borgia R., Mancia M. Proencephalic mechanisms of ECoG desynchronization in cerveau isolé cats. Electroenceph. Clin. Neurophysiol. 42:1977;213-235.
9. Berger-Sweeney J., Heckers S., Mesulam M.-M., Wiley R.G., Lappi D.A., Sharma M. Differential effects on spatial navigation of immunotoxin-induced cholinergic lesions of the medial septal area and nucleus basalis magnocellularis. J. Neurosci. 14:1994;4507-4519.
10. Biggan S.L., Beninger R.J., Cockhill J., Jhamandas K., Boegman R.J. Quisqualate lesions of rat NBM: selective effects on working memory in a double Y-maze. Brain Res. Bull. 26:1991;613-616.
11. Bigl V., Schliebs R. Simulation of cortical cholinergic deficits-a novel experimental approach to study pathogenetic aspects of Alzheimer's disease. J. Neural Transm. 54:(Suppl.):1998;237-247.
12. Blokland A. Acetylcholine: a neurotransmitter for learning and memory? Brain Res. Rev. 21:1996;285-300.
13. Bondareff W., Mountjoy C.Q., Roth M. Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus ceruleus) in senile dementia. Neurology. 32:1982;164-168.
14. Bowen D.M., Davison A.N. Biochemical studies of nerve cells and energy metabolism in Alzheimer's disease. Br. Med. Bull. 42:1986;75-80.
15. Buzsáki G., Gage F.H. The cholinergic nucleus basalis, a key structure in neocortical arousal. Frotscher M., Misgeld U. Central Cholinergic Synaptic Transmission. 1989;159-171 Birkhäuser, Basel.
16. Cacabelos R., Yamatodani A., Niigawa H., Hariguchi S., Tada K., Nishimura T., Wada H., Brandeis L., Pearson J. Brain histamine in Alzheimer's disease. Methodol. Find. Exp. Clin. Pharmacol. 11:1989;353-360.
17. Cain D.P. Testing the NMDA, long-term potentiation and cholinergic hypotheses of spatial learning. Neurosci. Biobehav. Rev. 22:1998;181-193.
18. Casamenti F., Deffenu G., Abbamondi A., Pepeu G. Changes in cortical acetylcholine output induced by modulation of the nucleus basalis. Brain Res. Bull. 16:1986;689-695.
19. Celesia G.G., Jasper H.H. Acetylcholine release from cerebral cortex in relation to state of activation. Neurology. 16:1966;1053-1063.
20. Chappell J., McMahan R., Chiba A., Gallagher M. A re-examination of the role of basal forebrain cholinergic neurons in spatial working memory. Neuropharmacology. 37:1998;481-487.
21. Coben L.A., Danziger W., Storandt M. A longitudinal EEG study of mild senile dementia of Alzheimer's type: Changes at 1 year and at 2.5 years. .Electroencephalogr. Clin. Neurophysiol. 61:1985;101-112.
22. Collerton D. Cholinergic function and intellectual decline in Alzheimer's disease. Neuroscience. 19:1986;1-28.
23. Coyle J.T., Price D.L., DeLong M.R. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science. 291:1983;1184-1190.
24. Cross A.J. Serotonin in Alzheimer-type dementia and other dementing illnesses. Ann. N. Y. Acad. Sci. 600:1990;405-415.
25. Cross A.J., Crow T.J., Perry E.K., Perry R.H., Blessed G., Tomlinson B.E. Reduced dopamine-beta-hydroxylase activity in Alzheimer's disease. Br. Med. J. 282:1981;93-94.
26. Cuculic Z., Bost K., Himwich H.E. An examination of a possible cortical cholinergic link in the EEG arousal reaction. Prog. Brain Res. 28:1968;27-39.
27. Davies P. Neurotransmitter-related enzymes in senile dementia of the Alzheimer type. Brain Res. 171:1979;319-327.
28. Davies P., Katzman R., Terry R.D. Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementa. Nature. 288:1980;279-280.
29. Decker M., McGaugh J.L. The role of interactions between the cholinergic system and other neuromodulatory systems in learning and memory. Synapse. 7:1991;151-168.
30. Détári L., Rasmusson D.D., Semba K. The role of basal forebrain neurons in tonic and phasic activation of the cerebral cortex. Prog. Neurobiol. 58:1999;249-277.
31. Dornan W.A., McCampbell A.R., Tinkler G.P., Hickman U., Bannon A.W., Decker M.W., Gunther K.L. Comparison of site-specific injections into the basal forebrain on water maze and radial arm maze performance in the male rat after immunolesioning with 192 IgG saporin. Behav. Brain Res. 82:1996;93-101.
32. Drachman D.A. Memory and cognitive function in man: does the cholinergic system have a specific role? Neurology. 27:1977;783-790.
33. Drachman D.A., Leavitt J. Human memory and the cholinergic system: a relationship to aging. Arch. Neurol. 30:1974;113-121.
34. Dringenberg H.C., Vanderwolf C.H. 5-Hydroxytryptamine (5-HT) agonists: effects on neocortical slow wave activity after combined muscarinic and serotonergic blockade. Brain Res. 728:1996;181-187.
35. Dringenberg H.C., Vanderwolf C.H. Involvement of direct and indirect pathways in electrocorticographic activation. Neurosci. Biobehav. Rev. 22:1998;243-257.
36. Dringenberg H.C., Zalan R.M. Serotonin-dependent maintenance of spatial performance and EEG activation after cholinergic blockade: effects of serotonergic receptor antagonists. Brain Res. 837:1999;242-253.
37. Dubois B., Mayo W., Agid Y., Le Moal M., Simon H. Profound disturbances of spontaneous and learned behaviors following lesions of the nucleus basalis magnocellularis in the rat. Brain Res. 338:1985;249-258.
38. Farlow M.R., Evans R.M. Pharmacologic treatment of cognition in Alzheimer's dementia. Neurology. 51:(Suppl. 1):1998;S36-S44.
39. Fenton G.W. Electrophysiology of Alzheimer's disease. Br. Med. Bull. 42:1986;29-33.
40. Fox N.C., Warrington E.K., Seiffer A.L., Agnew S.K., Rossor M.N. Presymptomatic cognitive deficits in individuals at risk of familial Alzheimer's disease. Brain. 121:1998;1631-1639.
41. Francis P.T., Palmer A.M., Snape M., Wilcock G.K. The cholinergic hypothesis of Alzheimer's disease, a review of progress. J. Neurol. Neurosurg. Psychiatry. 66:1999;137-147.
42. Funderburk W.H., Case T.J. The effect of atropine on cortical potentials. Electroencephalogr. Clin. Neurophysiol. 3:1951;213-233.
43. Geula C.G. Abnormalities of neural circuitry in Alzheimer's disease: hippocampus and cortical cholinergic innervation. Neurology. 51:(Suppl. 1):1998;S18-S29.
44. Greenamyre J.T. The role of glutamate in neurotransmission and in neurologic disease. Arch. Neurol. 43:1986;1058-1063.
45. Greene J.D., Baddeley D., Hodges J.R. Analysis of the episodic memory deficit in early Alzheimer's disease: evidence from the Doors and People Test. Neuropsychologia. 34:1996;537-551.
46. Haroutunian V., Santucci A.C., Davis K.I.L. Implications of multiple transmitter system lesions for cholinomimetic therapy in Alzheimer's disease. Prog. Brain Res. 84:1990;333-346.
47. Hodges J. The amnestic predrome of Alzheimer's disease. Brain. 121:1998;1601-1602.
48. Holschneider D.P., Waite J.J., Leuchter A.F., Walton N.Y., Scremin O.U. Changes in electrocortical power and coherence in response to the selective cholinergic immunotoxin 192 IgG-saporin. Exp. Brain Res. 126:1999;270-280.
49. Jelic V., Dierks T., Ambela K., Almkvist O., Winblad B., Nordberg A. Longitudinal changes in quantitative EEG during long-term tacrine treatment in patients with Alzheimer's disease. Neurosci. Lett. 254:1998;85-88.
50. Kanai T., Szerb J.C. Mesencephalic reticular activating system and cortical acetylcholine output. Nature. 205:1965;80-82.
51. Katzman R. Current research on Alzheimer's disease in a historical perspective. Khachaturian Z.S., Radebaugh T.S. Alzheimer's Disease: Cause(s), Diagnosis, Treatment, and Care. 1996;15-29 CRC Press, Boca Raton, FL.
52. Khachaturian Z.S., Radebaugh T.S. Alzheimer's Disease: Cause(s), Diagnosis, Treatment, and Care. 1996;CRC Press, Boca Raton, FL.
53. Lakmache Y., Lassonde M., Gauthier S., Frigon J.-Y., Lepore F. Interhemispheric disconnection syndrome in Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 95:1998;9042-9046.
54. Leanza G., Nilsson O.G., Wiley R.G., Björklund A. Selective lesioning of the basal forebrain cholinergic system by intraventricular 192 IgG-saporin: behavioural, biochemical and stereological studies in the rat. Eur. J. Neurosci. 7:1995;329-343.
55. Lin L., LeBlanc C.J., Deacon T.W., Isacson O. Chronic cognitive deficits and amyloid precursor protein elevation after selective immunotoxin lesions of the basal forebrain cholinergic system. NeuroReport. 9:1998;547-552.
56. Locatelli T., Cursi M., Liberati D., Franceschi M., Comi G. EEG coherence in Alzheimer's disease. Electroencephalogr. Clin. Neurophysiol. 106:1998;229-237.
57. Maragos W.F., Greenamyre J.T., Penney J.B., Youngm A.B. Glutamate dysfunction in Alzheimer's disease: a hypothesis. Trends Neurosci. 10:1987;65-68.
58. Mazurkiewicz-Kwilecki I.M., Nsonwah S. Changes in the regional brain histamine and histidine levels in postmortem brains of Alzheimer's patients. Can J. Physiol. Pharmacol. 67:1989;75-78.
59. McAdam W., Robinson R.A. Senile intellectual deterioration and the electroencephalogram: a quantitative correlation. J. Ment. Sci. 102:1956;438-445.
60. McEntee W.J., Crook T.H. Serotonin, memory, and the aging brain. Pychopharmacology. 103:1991;143-149.
61. 18F]altanserin to serotonin in type 2A receptors in aging: persistence of effect after partial volume correction. Brain Res. 813:1996;167-171.
62. Mesulam M.-M., Mufson E.J., Wainer B.H., Levey A.I. Central cholinergic pathways in the rat: an overview based on an alternative nomenclature (Ch1-Ch6). Neuroscience. 10:1983;1185-1201.
63. Metherate R., Cox C.L., Ashe J.H. Cellular bases of neocortical activation: modulation of neural oscillations by the nucleus basalis and endogenous acetylcholine. J. Neurosci. 12:1992;4701-4711.
64. Morris J.C. Diagnosis of Alzheimer's disease. Khachaturian Z.S., Radebaugh T.S. Alzheimer's Disease: Cause(s), Diagnosis, Treatment, and Care. 1996;75-84 CRC Press, Boca Raton, FL.
65. Muir J.L. Acetylcholine, aging, and Alzheimer's disease. Pharmacol. Biochem. Behav. 56:1997;687-696.
66. Myhrer T. Adverse psychological impact, glutamatergic dysfunction, and risk factors for Alzheimer's disease. Neurosci. Biobehav. Rev. 23:1998;131-139.
67. Neuman R.S., Zebrowska G. Serotonin (5-HT2) receptor mediated enhancement of cortical unit activity. Can. J. Physiol. Pharmacol. 70:1992;1604-1609.
68. Nilsson O.G., Strecker R.E., Daszuta A., Björklund A. Combined cholinergic and serotonergic denervation of the forebrain produces severe deficits in a spatial learning tasks in the rat. Brain Res. 453:1988;235-246.
69. Page K.J., Everitt B.J., Robbins T.W., Marston H.M., Wilkinson L.S. Dissociable effects on spatial maze and passive avoidance acquisition and retention following AMPA and ibotenic acid-induced excitotoxic lesions of the basal forebrain in rats: differential dependence on cholinergic neuronal loss. Neuroscience. 43:1991;457-472.
70. Palmer A.M., Francis P.T., Benton J.S., Sims N.R., Mann M.A., Neary D., Snowdon J.S., Bowen D.M. Presynaptic serotonergic dysfunction in patients with Alzheimer's disease. J. Neurochem. 48:1987;8-15.
71. Penttilä M., Partanen J.V., Soininen H., Riekkinen P.J. Quantitative analysis of occipital EEG in different stages of Alzheimer's disease. Electroencephalogr. Clin. Neurophysiol. 60:1985;1-6.
72. Perry R.H., Dockray G.J., Dimaline R., Perry E.K., Blessed G., Tomlinson B.E. Neuropeptides in Alzheimer's disease, depression and schizophrenia. J. Neurol. Sci. 51:1981;465-472.
73. Piccinin G.L., Finali G., Piccirilli M. Neuropsychological effects of I-deprenyl in Alzheimer's type dementia. Clin. Neuropharmacol. 13:1990;147-163.
74. Prichep L.S., John E.R., Ferds S.H., Reisberg B., Almas M., Alper K., Cancro R. Quantitative EEG correlates of cognitive deterioration in the elderly. Neurobiol. Aging. 15:1994;85-90.
75. Ray P.G., Jackson W.J. Lesions of the nucleus basalis alter ChAT activity and EEG in rat frontal cortex. Electroencephalogr. Clin. Neurophysiol. 79:1991;62-68.
76. Reynolds G.P., Mason S.L., Meldrum A., De Keczer S., Parnes H., Eglen R.M., Wong E.H.F. 5-Hydroxytryptamine (5-HT) receptors in postmortem human brain tissue: distribution, pharmacology and effects of neurodegenerative diseases. Br. J. Pharmacol. 114:1995;993-998.
77. Richter-Levin G., Segal M. Spatial performance is severely impaired in rats with combined reduction in serotonergic and cholinergic transmission. Brain Res. 477:1989;404-407.
78. Richter-Levin G., Segal M. The effects of serotonin depletion and raphe grafts on hippocampal electrophysiology and behavior. J. Neurosci. 11:1991;1585-1596.
79. Riekkinen P. Jr, Jäkälä P., Sirviö J., Koivisto E., Miettinen R., Riekkinen P. The effects of THA on scopolamine and nucleus basalis lesion-induced EEG slowing. Brain Res. Bull. 26:1991;633-637.
80. Riekkinen M., Riekidnen P., Sirviö J., Rieiddnen P. Jr. Effects of combined methysergide and mecamylamine 1 scopolamine treatment on spatial navigation. Brain Res. 585:1992;322-326.
81. Riekidnen P. Jr, Sirviö J., Riekkinen P. Interaction between raphe dorsalis and nucleus magnocellularis in spatial learning. Brain Res. 527:1990;342-345.
82. Robertson B.J., Boon F., Cain D.P., Vanderwolf C.H. Behavioral effects of antimuscarinic, anti-serotonergic, and anti-NMDA treatments: hippocampal and neocortical slow wave electrophysiology predict the effects on grooming in the rat. Brain Res. 838:1999;234-240.
83. Rossor M., lversen L.L. Non-cholinergic neurotransmitter abnormalities in Alzheimer's disease. Br. Med. Bull. 42:1986;70-74.
84. Ruatsalainen S., Miettinen R., MacDonald E., Riekkinen M., Sirvilö J. The role of the dorsal raphe-serotonergic system and cholinergic receptors in the modulation of working memory. Neurosci. Biobehav. Rev. 22:1998;21-31.
85. Saucier D., Hargreaves E.L., Boon F., Vanderwolf C.H., Cain D.P. Detailed behavioral analysis of water maze acquisition under systemic NMDA or muscarinic antagonism: nonspatial pretraining eliminates spatial learning deficits. Behav. Neurosci. 110:1996;103-116.
86. Schneider L.S., Olin J.T., Pawluczyk S. A double-blind crossover pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease. Am. J. Psychiatry. 150:1993;321-323.
87. Schneider L.S., Pollock V.E., Zemansky M.F., Gleason R.P., Palmer R., Sloane B. A pilot study of low-dose 1-deprenyl in Alzheimer's disease. J. Geriatr. Psychiatry Neurol. 4:1991;143-148.
88. Schneider C., Risser D., Kirchner L., Kitzmüller E., Cairns N., Prast H., Singwald N., Lubec G. Similar deficits of central histaminergic system in patients with Down syndrome and Alzheimer's disease. Neurosci. Lett. 222:1997;183-186.
89. Semba K. The cholinergic basal forebrain: a critical role in cortical arousal. In: Napier TC, Kalivas PW, Hanin I, editors. The Basal Forebrain: Anatomy to Function. New York: Plenum Press, 1991. pp. 197-218.
90. Semba K., Fiber H.C. Organization of central cholinergic systems. Prog. Brain Res. 79:1989;37-63.
91. Spehlmann R., Norcross K. Cholinergic mechanisms in the production of focal cortical slow waves. Experientia. 38:1982;109-111.
92. Spillantini M.G., Goedert M. Tau protein pathology in neurodegenerative diseases. Trends Neurosci. 21:1998;428-433.
93. Squire L.R. Memory and Brain. 1987;Oxford University Press, New York.
94. Stewart D.J., MacFabe D.F., Vanderwolf C.H. Cholinergic activation of the electrocorticogram: role of the substantia innominata and effects of atropine and quinudidinyl benzilate. Brain Res. 322:1984;219-232.
95. Sutherland R.J., Whishaw I.Q., Regehr J.C. Cholinergic receptor blockade impairs spatial localization by use of distal cues in the rat. J. Comp. Physiol. Psychol. 96:1982;563-573.
96. Tarbit I., Perry E.K., Perry R.H., Blessed G., Tomlinson B.E. Hippocampal free amino acids in Alzheimer's disease. J. Neurochem. 35:1980;1246-1249.
97. Terry R.D., Wisniewski H.M. Ultrastructure of senile dementia and of experimental analogues. Gaitz C.M. Aging and the Brain. 1972;89-116 Plenum Press, New York.
98. Törk I. Anatomy of the serotonergic system. Ann. NY Acad. Sci. 600:1990;9-35.
99. Torres E.M., Perry T.A., Blokland A., Wilkinson L.S., Wiley R.G., Lappi D.A., Dunnett S.B. Behavioural, histochemical and biochemical consequences of selective immunolesions in discrete regions of the basal forebrain cholinergic system. Neuroscience. 63:1994;95-122.
100. Vanderwolf C.H. Aminergic control of the electrocorticogram: a progress report. Boulton A.A., Baker G.B., Dewhurst W.G., Sandler M. Neurobiology of the Trace Amines. 1984;163-183 Humana Press, Totowa, NJ.
101. Vanderwolf C.H. Cerebral activity and behavior: control by central cholinergic and serotonergic systems. Int. Rev. Neurobiol. 30:1988;225-340.
102. Vanderwolf C.H. A general role for serotonin in the control of behavior: studies with intracerebral 5,7-dihydroxytryptamine. Brain Res. 504:1989;192-198.
103. Vanderwolf C.H., Baker G.B. Evidence that serotonin mediates non-cholinergic neocortical low voltage fast activity, non-cholinergic hippocampal rhythmical slow activity and contributes to intelligent behavior. Brain Res. 374:1986;342-356.
104. Vanderwolf C.H., Baker G.B. The role of brain noradrenaline in cortical activation and behavior: a study of lesions of the locus coeruleus, medial thalamus and hippocampus-neocortex and of muscarinic blockade in the rat. Behav. Brain Res. 78:1996;225-234.
105. Vanderwolf C.H., Baker G.B., Dickson C. Serotonergic control of cerebral activity and behavior: models of dementia. Ann. NY Acad. Sci. 600:1990;366-383.
106. Vanderwolf C.H., Cain D.P. The behavioral neurobiology of learning and memory: a conceptual reorientation. Brain Res. Rev. 19:1994;264-297.
107. Vanderwolf C.H., Raithby A., Snider M., Cristi C., Tanner C. Effects of some cholinergic agonists on neocortical slow wave activity in rats with basal forebrain lesions. Brain Res. Bull. 31:1993;515-521.
108. Whishaw I.Q. Cholinergic receptor blockade in the rat impairs locale but not taxon strategies for place navigation in a swimming pool. Behav. Neurosci. 99:1985;979-1005.
109. Whishaw I.Q., O'Connor W.T., Dunnett S.B. Disruption of central cholinergic systems in the rat by basal forebrain lesions or atropine: effects on feeding, sensorimotor behaviour, locomotor activity and spatial navigation. Behav. Brain Res. 17:1985;103-115.
110. Winkler J., Suhr S.T., Gage F.H., Thai W., Fisher U. Essential role of neocortical acetylcholine in spatial memory. Nature. 375:1995;484-487.
111. Woolf N.J. Cholinergic systems in the mammalian brain and spinal cord. Prog. Neurobiol. 37:1991;475-524.
112. Yamamoto T., Hirano A. Nucleus raphe dorsalis in Alzheimer's disease: neurofibrillary tangles and loss of large neurons. Ann. Neurol. 17:1985;573-577.